These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

336 related items for PubMed ID: 22877926

  • 1. What do we know about the reduction of Pt(IV) pro-drugs?
    Wexselblatt E, Gibson D.
    J Inorg Biochem; 2012 Dec; 117():220-9. PubMed ID: 22877926
    [Abstract] [Full Text] [Related]

  • 2. Beyond mere DNA damage: Recent progress in platinum(IV) anticancer complexes containing multi-functional axial ligands.
    Deng Z, Zhu G.
    Curr Opin Chem Biol; 2023 Jun; 74():102303. PubMed ID: 37075513
    [Abstract] [Full Text] [Related]

  • 3. Multiaction Pt(IV) Carbamate Complexes Can Codeliver Pt(II) Drugs and Amine Containing Bioactive Molecules.
    Babu T, Sarkar A, Karmakar S, Schmidt C, Gibson D.
    Inorg Chem; 2020 Apr 06; 59(7):5182-5193. PubMed ID: 32207294
    [Abstract] [Full Text] [Related]

  • 4. A Cancer Cell-Selective and Low-Toxic Bifunctional Heterodinuclear Pt(IV)-Ru(II) Anticancer Prodrug.
    Ma L, Lin X, Li C, Xu Z, Chan CY, Tse MK, Shi P, Zhu G.
    Inorg Chem; 2018 Mar 05; 57(5):2917-2924. PubMed ID: 29436828
    [Abstract] [Full Text] [Related]

  • 5. Optimization of axial ligands to promote the photoactivation of BODIPY-conjugated platinum(IV) anticancer prodrugs.
    Yao H, Gunawan YF, Liu G, Tse MK, Zhu G.
    Dalton Trans; 2021 Oct 12; 50(39):13737-13747. PubMed ID: 34519297
    [Abstract] [Full Text] [Related]

  • 6. Oxidation of anticancer Pt(II) complexes with monodentate phosphane ligands: towards stable but active Pt(IV) prodrugs.
    Medrano MÁ, Álvarez-Valdés A, Perles J, Lloret-Fillol J, Muñoz-Galván S, Carnero A, Navarro-Ranninger C, Quiroga AG.
    Chem Commun (Camb); 2013 May 25; 49(42):4806-8. PubMed ID: 23591566
    [Abstract] [Full Text] [Related]

  • 7. Design and investigation of photoactivatable platinum(iv) prodrug complexes of cisplatin.
    Lee VEY, Chin CF, Ang WH.
    Dalton Trans; 2019 Jun 07; 48(21):7388-7393. PubMed ID: 30957798
    [Abstract] [Full Text] [Related]

  • 8. Finely Tuned Asymmetric Platinum(IV) Anticancer Complexes: Structure-Activity Relationship and Application as Orally Available Prodrugs.
    Yap SQ, Chin CF, Hong Thng AH, Pang YY, Ho HK, Ang WH.
    ChemMedChem; 2017 Feb 20; 12(4):300-311. PubMed ID: 28028938
    [Abstract] [Full Text] [Related]

  • 9. Cancer-Specific, Intracellular, Reductive Activation of Anticancer PtIV Prodrugs.
    Reshetnikov V, Daum S, Mokhir A.
    Chemistry; 2017 Apr 27; 23(24):5678-5681. PubMed ID: 28319647
    [Abstract] [Full Text] [Related]

  • 10. Chemistry and biological activity of platinum amidine complexes.
    Michelin RA, Sgarbossa P, Sbovata SM, Gandin V, Marzano C, Bertani R.
    ChemMedChem; 2011 Jul 04; 6(7):1172-83. PubMed ID: 21630470
    [Abstract] [Full Text] [Related]

  • 11. Electrodrugs: an electrochemical prodrug activation strategy.
    Norman DJ, González-Fernández E, Clavadetscher J, Tucker L, Staderini M, Mount AR, Murray AF, Bradley M.
    Chem Commun (Camb); 2018 Aug 14; 54(66):9242-9245. PubMed ID: 30066701
    [Abstract] [Full Text] [Related]

  • 12. Dinuclear Pt(II)-bisphosphonate complexes: a scaffold for multinuclear or different oxidation state platinum drugs.
    Piccinonna S, Margiotta N, Pacifico C, Lopalco A, Denora N, Fedi S, Corsini M, Natile G.
    Dalton Trans; 2012 Aug 28; 41(32):9689-99. PubMed ID: 22782180
    [Abstract] [Full Text] [Related]

  • 13. Facile preparation of mono-, di- and mixed-carboxylato platinum(IV) complexes for versatile anticancer prodrug design.
    Zhang JZ, Bonnitcha P, Wexselblatt E, Klein AV, Najajreh Y, Gibson D, Hambley TW.
    Chemistry; 2013 Jan 28; 19(5):1672-6. PubMed ID: 23255183
    [Abstract] [Full Text] [Related]

  • 14. Synthesis, Structure, and Cytotoxicity of Oxaliplatin-Based Platinum(IV) Anticancer Prodrugs Bearing One Axial Fluoride.
    Xu Z, Chan HM, Li C, Wang Z, Tse MK, Tong Z, Zhu G.
    Inorg Chem; 2018 Jul 16; 57(14):8227-8235. PubMed ID: 29943979
    [Abstract] [Full Text] [Related]

  • 15. Platinum(iv) anticancer prodrugs - hypotheses and facts.
    Gibson D.
    Dalton Trans; 2016 Aug 16; 45(33):12983-91. PubMed ID: 27214873
    [Abstract] [Full Text] [Related]

  • 16. Dual targeting of hypoxic and acidic tumor environments with a cobalt(III) chaperone complex.
    Yamamoto N, Renfrew AK, Kim BJ, Bryce NS, Hambley TW.
    J Med Chem; 2012 Dec 27; 55(24):11013-21. PubMed ID: 23199008
    [Abstract] [Full Text] [Related]

  • 17. Platinum(IV) anticancer agents; are we en route to the holy grail or to a dead end?
    Gibson D.
    J Inorg Biochem; 2021 Apr 27; 217():111353. PubMed ID: 33477089
    [Abstract] [Full Text] [Related]

  • 18. Stability, Reduction, and Cytotoxicity of Platinum(IV) Anticancer Prodrugs Bearing Carbamate Axial Ligands: Comparison with Their Carboxylate Analogues.
    Chen S, Yao H, Zhou Q, Tse MK, Gunawan YF, Zhu G.
    Inorg Chem; 2020 Aug 17; 59(16):11676-11687. PubMed ID: 32799457
    [Abstract] [Full Text] [Related]

  • 19. Layer-by-layer assembled polypeptide capsules for platinum-based pro-drug delivery.
    Zhou D, Xiao H, Meng F, Zhou S, Guo J, Li X, Jing X, Huang Y.
    Bioconjug Chem; 2012 Dec 19; 23(12):2335-43. PubMed ID: 23176570
    [Abstract] [Full Text] [Related]

  • 20. Synthesis, characterization, and cytotoxicity of dinuclear platinum-bisphosphonate complexes to be used as prodrugs in the local treatment of bone tumours.
    Margiotta N, Ostuni R, Gandin V, Marzano C, Piccinonna S, Natile G.
    Dalton Trans; 2009 Dec 28; (48):10904-13. PubMed ID: 20023921
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 17.